Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure
Published: October 31, 2016
- Hypertension, obesity, diabetes, hyperlipidemia, and metabolic syndrome are common comorbidities in heart failure (HF). This statement summarizes and provides guidance for managing these in association with HF.
- All of these are associated with the development of incident heart failure; however, the role of these in persons with chronic HF is unpredictable and management is challenging.
- This scientific statement explores these five comorbidities using an evidence-based approach and discusses how to manage them.
Supporting Materials
- Commentary: Non-Paradoxical Paradoxes of Heart Failure by Maya Guglin, MD, PhD
- Top Things to Know: Top Things to Know
Recommended Reading
- 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guideline and the HF Society of America
- 2013 ACCF/AHA Guideline for the Management of Heart Failure
- Drugs That May Cause or Exacerbate Heart Failure
- Transitions of Care Heart Failure
- Forecasting the Impact of Heart Failure in the United States: A Policy Statement from the American Heart Association
- Heart Disease and Stroke Statistics 2016